SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-reco...
Saved in:
| Main Authors: | Abhishek Kansara, Faiza Mubeen, Jawairia Shakil |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Houston Methodist DeBakey Heart & Vascular Center
2022-09-01
|
| Series: | Methodist DeBakey Cardiovascular Journal |
| Subjects: | |
| Online Access: | https://account.journal.houstonmethodist.org/index.php/up-j-mdbcj/article/view/1120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01) -
Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01) -
Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01) -
Position of SGLT2i in prediabetes: A systematic review of literature
by: Kaushik Biswas, et al.
Published: (2025-04-01) -
Perioperative prevention of euglycaemic diabetic ketoacidosis in people living with type 2 diabetes established on sodium-glucose transport-2 inhibitors – a cross-site multi-cycle audit
by: Karl A. Romain, et al.
Published: (2025-09-01)